86299-41-4

Upstream product

• 20781-20-8 2,4-Dimethoxybenzylamine 
• 86390-73-0 N-<(3S,4S)-cis-1-(2,4-dimethoxybenzyl)-4-<(R)-2,2-dimethyl-1,3-dioxalan-4-yl>-2-oxo-3-azetidinyl>phthalimide 
• 86334-58-9 (3S,4S)-3-amino-1-(2,4-dimethoxybenzyl)-4-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)azetidin-2-one 
• 86334-59-0 benzyl ((2S,3S)-1-(2,4-dimethoxybenzyl)-2-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)-4-oxoazetidin-3-yl)-carbamate 
• 88852-09-9 (R,E)-1-(2,4-dimethoxyphenyl)-N-((2,2-dimethyl-1,3-dioxolan-4-yl)methylene)methanamine 
• 1138-80-3 N-(Benzyloxycarbonyl)glycine 

Downstream Products

• 99397-29-2 (3S,4S)-3-benzyloxycarbonylamino-4-hydroxymethyl-2-azetidinone 
• 113599-60-3 (3S,4S)-3-(benzyloxycarboxamido)-4-<<(tert-butyldimethylsilyl)oxy>methyl>-2-azetidinone 

Relevant academic research and scientific papers

Process Development for the Synthesis of a Monobactam Antibiotic-LYS228

A scalable process for the novel monobactam antibiotic LYS228 has been developed. This paper covers a novel scalable process for producing β-lactam 10 in the multiple kilogram scale. An alternative approach to compound 7 without protecting-group exchange

SALTS AND SOLID FORMS OF MONOBACTAM ANTIBIOTIC

Providing new solid forms, salts and polymorphs of 1-(((Z)-(1-(2-aminothiazol-4-yl) -2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl) amino)ethylidene)amino)oxy)-cyclopropanecarboxylic acid (referred to herein as compound X), pharmaceutical compositions containing them, and processes for their manufacture and use in therapy.

MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS

This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.